A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
Status:
Not yet recruiting
Trial end date:
2023-07-08
Target enrollment:
Participant gender:
Summary
This is a prospective, parallel-comparison, multi-center, double-masked, randomized,
vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy
of VVN539 in subjects with POAG or OHT. Three different dosing regimens (once a day [q.d.] in
the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days, each.